The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings

Harvard Review of Psychiatry

Volumn 21, Issue 5, 2013, Pages 219-247

  Cochran, David M ^a   Fallon, Daniel ^b   Hill, Michael ^a   Frazier, Jean A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anxiety; Anxiety disorders; Autism; Humans; Mood disorders; Oxytocin; Schizophrenia

Indexed keywords

APOMORPHINE; CLOZAPINE; ESCITALOPRAM; MESSENGER RNA; NEUROPHYSIN; NEUROPHYSIN II; OXYTOCIN; OXYTOCIN RECEPTOR; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG; VASOPRESSIN; OXYTOCIC AGENT; PSYCHOTROPIC AGENT;

ANXIETY DISORDER; ASPERGER SYNDROME; AUTISM; BIPOLAR DEPRESSION; BORDERLINE STATE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; COMPARATIVE STUDY; COMPULSION; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE TITRATION; ELECTROCONVULSIVE THERAPY; EPIGENETICS; FIBROMYALGIA; FOLLOW UP; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MENTAL DISEASE; MOOD DISORDER; NEGATIVE SYNDROME; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OXYTOCIN BLOOD LEVEL; PERSONALITY DISORDER; POSITIVE SYNDROME; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL COGNITION; SOCIAL PHOBIA; TIC; TREATMENT DURATION; TREATMENT RESPONSE; EMOTIONAL INTELLIGENCE; HUMAN RELATION; MENTAL DISORDERS; METABOLISM; PHYSIOLOGY; SOCIAL BEHAVIOR;

EMOTIONAL INTELLIGENCE; EPIGENOMICS; HUMANS; INTERPERSONAL RELATIONS; MENTAL DISORDERS; OXYTOCICS; OXYTOCIN; PSYCHOPATHOLOGY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIAL BEHAVIOR;

EID: 84888215880     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0b013e3182a75b7d     Document Type: Review

References (139)

1. SwaabDF, PoolCW,Nijveldt F. Immunofluorescence of vasopressin and oxytocin in the rat hypothalamo-neurohypophypopseal system. J Neural Transm 1975;36:195-215.
2. Pittman QJ, Blume HW, Renaud LP. Connections of the hypothalamic paraventricular nucleus with the neurohypophysis, median eminence, amygdala, lateral septum and midbrain periaqueductal gray: an electrophysiological study in the rat. Brain Res 1981;215:15-28.
3. Insel TR, Young LJ. The neurobiology of attachment. Nat Rev Neurosci 2001;2:129-36.
4. Macdonald K, Macdonald TM. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 2010;18:1-21.
5. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003;54:1389-98.
6. Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005;25:11489-93.
7. Domes G, Heinrichs M, Glascher J, Buchel C, Braus DF, Herpertz SC. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 2007;62:1187-90.
8. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 2005;435:673-6.
9. DomesG,Heinrichs M, Michel A, Berger C,Herpertz SC.Oxytocin improves "mind-reading" in humans. Biol Psychiatry 2007;61:731-3.
10. Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 2008;63:3-5.
11. Van IJzendoorn MH, Bakermans-Kranenburg MJ. A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to ingroup, and trust to out-group. Psychoneuroendocrinology 2012;37:438-43.
12. Shamay-Tsoory SG, Fischer M, Dvash J, Harari H, Perach- Bloom N, Levkovitz Y. Intranasal administration of oxytocin increases envy and schadenfreude (gloating). Biol Psychiatry 2009;66:864-70.
13. Stallen M, De Dreu CK, Shalvi S, Smidts A, Sanfey AG. The herding hormone: oxytocin stimulates in-group conformity. Psychol Sci 2012;23:1288-92.
14. De Dreu CK, Shalvi S, Greer LL, Van Kleef GA, Handgraaf MJ. Oxytocin motivates non-cooperation in intergroup conflict to protect vulnerable in-group members. PLoS One 2012;7:e46751.
15. Sheng F, Liu Y, Zhou B, ZhouW, Han S. Oxytocin modulates the racial bias in neural responses to others' suffering. Biol Psychol 2013;92:380-6.
16. Feldman R, Weller A, Zagoory-Sharon O, Levine A. Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding. Psychol Sci 2007;18:965-70.
17. Feldman R, Gordon I, Schneiderman I, Weisman O, Zagoory-Sharon O. Natural variations in maternal and paternal care are associated with systematic changes in oxytocin following parent-infant contact. Psychoneuroendocrinology 2010;35:1133-41.
18. Feldman R, Gordon I, Zagoory-Sharon O. Maternal and paternal plasma, salivary, and urinary oxytocin and parentinfant synchrony: considering stress and affiliation components of human bonding. Dev Sci 2011;14:752-61.
19. Levine A, Zagoory-Sharon O, Feldman R, Weller A. Oxytocin during pregnancy and early postpartum: individual patterns and maternal-fetal attachment. Peptides 2007;28:1162-9.
20. Naber F, van Ijzendoorn MH, Deschamps P, van Engeland H, Bakermans-Kranenburg MJ. Intranasal oxytocin increases fathers' observed responsiveness during play with their children: a double-blind within-subject experiment. Psychoneuroendocrinology 2010;35:1583-6.
21. Galbally M, Lewis AJ, Ijzendoorn M, Permezel M. The role of oxytocin in mother-infant relations: a systematic review of human studies. Harv Rev Psychiatry 2011;19:1-14.
22. Wismer Fries AB, Ziegler TE, Kurian JR, Jacoris S, Pollak SD. Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior. Proc Natl Acad Sci U S A 2005;102:17237-40.
23. Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry 2009;14: 954-8.
24. Meinlschmidt G, Heim C. Sensitivity to intranasal oxytocin in adult men with early parental separation. Biol Psychiatry 2007;61:1109-11.
25. Bartz JA, Zaki J, Ochsner KN, et al. Effects of oxytocin on recollections of maternal care and closeness. Proc Natl Acad Sci U S A 2010;107:21371-5.
26. Buchheim A, HeinrichsM, George C, et al. Oxytocin enhances the experience of attachment security. Psychoneuroendocrinology 2009;34:1417-22.
27. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998;43:270-7.
28. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001;50:609-13.
29. Jansen LM, Gispen-de Wied CC, Wiegant VM, Westenberg HG, Lahuis BE, van Engeland H. Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord 2006;36: 891-9.
30. Wu S, Jia M, Ruan Y, et al. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry 2005;58:74-7.
31. Jacob S, Brune CW, Carter CS, Leventhal BL, Lord C, Cook EH Jr. Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett 2007;417:6-9.
32. Lerer E, Levi S, Salomon S, Darvasi A, Yirmiya N, Ebstein RP. Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry 2008;13:980-8.
33. Yrigollen CM, Han SS, Kochetkova A, et al. Genes controlling affiliative behavior as candidate genes for autism. Biol Psychiatry 2008;63:911-6.
34. Liu X, Kawamura Y, Shimada T, et al. Association of the oxytocin receptor (OXTR) gene polymorphisms with autism spectrum disorder (ASD) in the Japanese population. J Hum Genet 2010;55:137-41.
35. Tansey KE, Brookes KJ, Hill MJ, et al. Oxytocin receptor (OXTR) does not play a major role in the aetiology of autism: genetic and molecular studies. Neurosci Lett 2010;474:163-7.
36. Wermter AK, Kamp-Becker I, Hesse P, Schulte-Korne G, Strauch K, Remschmidt H. Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:629-39.
37. Campbell DB, Datta D, Jones ST, et al. Association of oxytocin receptor (OXTR) gene variants with multiple phenotype domains of autism spectrum disorder. J Neurodev Disord 2011;3:101-12.
38. Gregory SG, Connelly JJ, Towers AJ, et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med 2009;7:62.
39. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003; 28:193-8.
40. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007;61:498-503.
41. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67:692-4.
42. Bartz JA, Zaki J, Bolger N, et al. Oxytocin selectively improves empathic accuracy. Psychol Sci 2010;21:1426-8.
43. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in highfunctioning autism spectrum disorders. Proc Natl Acad Sci U S A 2010;107:4389-94.
44. Kosaka H, Munesue T, Ishitobi M, et al. Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry 2012;12:110.
45. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 2012;3:16.
46. Linkowski P, Geenen V, KerkhofsM,Mendlewicz J, Legros JJ. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 1984;234: 162-5.
47. Beckmann H, Lang RE, Gattaz WF. Vasopressin - oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 1985;10:187-91.
48. Legros JJ, Gazzotti C, Carvelli T, et al. Apomorphine stimulation of vasopressin- and oxytocin-neurophysins evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology 1992; 17:611-7.
49. Glovinsky D, Kalogeras KT, Kirch DG, Suddath R,Wyatt RJ. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr Res 1994;11: 273-6.
50. Goldman M, Marlow-O'Connor M, Torres I, Carter CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res 2008;98:247-55.
51. Keri S, Kiss I, Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci 2009;4:287-93.
52. Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res 2010;124:13-21.
53. Sasayama D, Hattori K, Teraishi T, et al. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res 2012;139:201-6.
54. Souza RP, Ismail P, Meltzer HY, Kennedy JL. Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res 2010;121:279-80.
55. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol 2010;13:793-8.
56. Teltsh O, Kanyas-Sarner K, Rigbi A, Greenbaum L, Lerer B, Kohn Y. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol 2011 Sep 7:1-11 [Epub ahead of print].
57. Montag C, Brockmann EM, Bayerl M, Rujescu D, Muller DJ, Gallinat J. Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study. World J Biol Psychiatry 2012 May 31 [Epub ahead of print].
58. Montag C, Brockmann EM, Lehmann A, Muller DJ, Rujescu D, Gallinat J. Association between oxytocin receptor gene polymorphisms and self-rated 'empathic concern' in schizophrenia. PLoS One 2012;7:e51882.
59. Watanabe Y, Kaneko N, Nunokawa A, Shibuya M, Egawa J, Someya T. Oxytocin receptor (OXTR) gene and risk of schizophrenia: case-control and family-based analyses and meta-analysis in a Japanese population. Psychiatry Clin Neurosci 2012;66:622.
60. Bakharev VD, Tikhomirov SM, Lozhkina TK. Psychotropic properties of oxytocin. Neurosci Behav Physiol 1986; 16:160-4.
61. Feifel D,Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 2010;68:678-80.
62. Goldman MB, Gomes AM, Carter CS, Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl) 2011; 216:101-10.
63. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr Res 2011;132:50-3.
64. Averbeck BB, Bobin T, Evans S, Shergill SS. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med 2011 Aug 11:1-8 [Epub ahead of print].
65. Feifel D, Macdonald K, Cobb P, Minassian A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res 2012;139:207-10.
66. Modabbernia A, Rezaei F, Salehi B, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebocontrolled study. CNS Drugs 2013;27:57-65.
67. Legros JJ, Geenen V, Linkowski P, Mendlewicz J. Increased neurophysin I and II cerbrospinal fluid concentration from bipolar versus unipolar depressed patients. Neuro Endocrinol Lett 1983;5:201-5.
68. Frasch A, Zetzsche T, Steiger A, Jirikowski GF. Reduction of plasma oxytocin levels in patients suffering from major depression. Adv Exp Med Biol 1995;395:257-8.
69. Pitts AF, Samuelson SD, Meller WH, Bissette G, Nemeroff CB, Kathol RG. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol Psychiatry 1995;38:330-5.
70. van Londen L, Goekoop JG, van Kempen GM, et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997;17:284-92.
71. van Londen L, Kerkhof GA, van den Berg F, et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998;43:196-204.
72. Van Londen L, Goekoop JG, Zwinderman AH, Lanser JB, Wiegant VM, De Wied D. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression. Psychol Med 1998;28: 275-84.
73. Anderberg UM, Uvnas-Moberg K. Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 2000; 59:373-9.
74. Scantamburlo G, Hansenne M, Fuchs S, et al. AVP- and OTneurophysins response to apomorphine and clonidine in major depression. Psychoneuroendocrinology 2005;30: 839-45.
75. Bell CJ, Nicholson H, Mulder RT, Luty SE, Joyce PR. Plasma oxytocin levels in depression and their correlation with the temperament dimension of reward dependence. J Psychopharmacol 2006;20:656-60.
76. Scantamburlo G, Hansenne M, Fuchs S, et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007;32:407-10.
77. Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM, Amico JA. Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom Med 2008; 70:967-75.
78. Ozsoy S, Esel E, Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009;169:249-52.
79. Parker KJ, Kenna HA, Zeitzer JM, et al. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res 2010;178:359-62.
80. Scott AI, Whalley LJ, Bennie J, Bowler G. Oestrogenstimulated neurophysin and outcome after electroconvulsive therapy. Lancet 1986;1:1411-4.
81. Scott AI, Whalley LJ, Legros JJ. Treatment outcome, seizure duration, and the neurophysin response to ECT. Biol Psychiatry 1989;25:585-97.
82. Scott AI, Shering PA, Lightman SL, Legros JJ, Whalley LJ. The release of oxytocin, vasopressin and associated neurophysins after electroconvulsive therapy. Hum Psychopharmacol 1991;6:161-4.
83. Smith JE, Williams K, Burkett S, Glue P, Nutt DJ. Oxytocin and vasopressin responses to ECT. Psychiatry Res 1990; 32:201-2.
84. Smith J, Williams K, Birkett S, Nicholson H, Glue P, Nutt DJ. Neuroendocrine and clinical effects of electroconvulsive therapy and their relationship to treatment outcome. Psychol Med 1994;24:547-55.
85. Devanand DP, Lisanby S, Lo ES, et al. Effects of electroconvulsive therapy on plasma vasopressin and oxytocin. Biol Psychiatry 1998;44:610-6.
86. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137-43.
87. Meynen G, Unmehopa UA, Hofman MA, Swaab DF, Hoogendijk WJ. Hypothalamic oxytocin mRNA expression and melancholic depression. Mol Psychiatry 2007; 12:118-9.
88. Costa B, Pini S, Gabelloni P, et al. Oxytocin receptor polymorphisms and adult attachment style in patients with depression. Psychoneuroendocrinology 2009;34:1506-14.
89. Thompson RJ, Parker KJ, Hallmayer JF, Waugh CE, Gotlib IH. Oxytocin receptor gene polymorphism (rs2254298) interacts with familial risk for psychopathology to predict symptoms of depression and anxiety in adolescent girls. Psychoneuroendocrinology 2011;36:144-7.
90. Pincus D, Kose S, Arana A, et al. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled FMRI study. Front Psychiatry 2010;1:134.
91. Scantamburlo G, AnsseauM, Geenen V, Legros JJ. Intranasal oxytocin as an adjunct to escitalopram in major depression. J Neuropsychiatry Clin Neurosci 2011;23:E5.
92. Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther 2008;14:165-70.
93. Hoge EA, Lawson EA, Metcalf CA, et al. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Depress Anxiety 2012;29: 924-30.
94. Pitman RK, Orr SP, Lasko NB. Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 1993; 48:107-17.
95. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009;34:917-23.
96. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010;35: 2403-13.
97. Labuschagne I, Phan KL, Wood A, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol 2011:1-14.
98. Swedo SE, Leonard HL, Kruesi MJ, et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessivecompulsive disorder. Arch Gen Psychiatry 1992;49:29-36.
99. Leckman JF, Goodman WK, North WG, et al. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry 1994;51:782-92.
100. Altemus M, Jacobson KR, Debellis M, et al. Normal CSF oxytocin and NPY levels in OCD. Biol Psychiatry 1999;45:931-3.
101. Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 1987;12:231-6.
102. Charles G, Guillaume R, Schittecatte M, Pholien P, Van Wettere JP, Wilmotte J. L'ocytocine dans le traitement du trouble obsessionnel: un rapport negatif a propos de deux cas. Psychiatrie & psychobiologie 1989;4:111-6.
103. den Boer JA, Westenberg HG. Oxytocin in obsessive compulsive disorder. Peptides 1992;13:1083-5.
104. Salzberg AD, Swedo SE. Oxytocin and vasopressin in obsessive-compulsive disorder. Am J Psychiatry 1992;149: 713-4.
105. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in trichotillomania. Biol Psychiatry 1996;40:559-60.
106. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry 1996;40: 547-9.
107. Lee R, Ferris C, Van de Kar LD, Coccaro EF. Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder. Psychoneuroendocrinology 2009;34:1567-73.
108. Bertsch K, Schmidinger I, Neumann ID, Herpertz SC. Reduced plasma oxytocin levels in female patients with borderline personality disorder. Horm Behav 2013;63:424-9.
109. Bartz J, Simeon D, Hamilton H, et al. Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci 2011;6:556-63.
110. Simeon D, Bartz J, Hamilton H, et al. Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. Psychoneuroendocrinology 2011;36: 1418-21.
111. Insel TR, O'Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry 1999;45:145-57.
112. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. Nat Genet 2000;25:284-8.
113. Takayanagi Y, Yoshida M, Bielsky IF, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A 2005;102:16096-101.
114. LordC,RutterM, LeCouteurA.AutismDiagnostic Interview- Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-85.
115. Lord C, Risi S, Lambrecht L, et al. The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000;30:205-23.
116. Constantino J, Gruber C. Social responsiveness scale (SRS). Los Angeles: Western Psychological Services, 2005.
117. Kusui C, Kimura T, Ogita K, et al. DNA methylation of the human oxytocin receptor gene promoter regulates tissuespecific gene suppression. Biochem Biophys Res Commun 2001;289:681-6.
118. Macdonald K, Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr 2012;24:130-46.
119. Legros JJ, Louis F. Identification of a vasopressin-neurophysin and of an oxytocin-neurophysin in man. Neuroendocrinology 1974;13:371-5.
120. Jones PM, Robinson IC. Differential clearance of neurophysin and neurohypophysial peptides fromthe cerebrospinal fluid in conscious guinea pigs. Neuroendocrinology 1982; 34:297-302.
121. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
122. Bujanow W. Hormones in the treatment of psychoses. Br Med J 1972;4:298.
123. Bujanow W. Letter: Is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J 1974;19:323.
124. Neumann ID, Wigger A, Torner L, Holsboer F, Landgraf R. Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol 2000;12:235-43.
125. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010;31:736-56.
126. Zetzsche T, Frasch A, Jirikowski G, Murck H, Steiger A. Nocturnal oxytocin secretion is reduced in major depression. Biol Psychiatry 1996;39:584.
127. Whalley LJ, Rosie R, Dick H, et al. Immediate increases in plasma prolactin and neurophysin but not other hormones after electroconvulsive therapy. Lancet 1982;2:1064-8.
128. Whalley LJ, Eagles JM, Bowler GM, et al. Selective effects of ECT on hypothalamic-pituitary activity. Psychol Med 1987;17:319-28.
129. Scott AI, Shering PA, Legros JJ, Whalley LJ. Improvement in depressive illness is not associated with altered release of neurophysins over a course of ECT. Psychiatry Res 1991;36:65-73.
130. Riddle WJ, Scott AI, Bennie J, Carroll S, Fink G. Current intensity and oxytocin release after electroconvulsive therapy. Biol Psychiatry 1993;33:839-41.
131. Lucht MJ, Barnow S, Sonnenfeld C, et al. Associations between the oxytocin receptor gene (OXTR) and affect, loneliness and intelligence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:860-6.
132. Alvares GA, Chen NT, Balleine BW, Hickie IB, Guastella AJ. Oxytocin selectively moderates negative cognitive appraisals in high trait anxious males. Psychoneuroendocrinology 2012;37:2022-31.
133. Theodoridou A, Rowe AC, Penton-Voak IS, Rogers PJ. Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. Horm Behav 2009;56:128-32.
134. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73.
135. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 2012;61:392-9.
136. Huffmeijer R, Alink LR, Tops M, et al. Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration. Neuro Endocrinol Lett 2012;33:21-5.
137. Ring RH, Schechter LE, Leonard SK, et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010;58: 69-77.
138. Pitt GR, Batt AR, Haigh RM, et al. Non-peptide oxytocin agonists. Bioorg Med Chem Lett 2004;14:4585-9.
139. Sabatier N. Alpha-melanocyte-stimulating hormone and oxytocin: a peptide signaling cascade in the hypothalamus. J Neuroendocrinol 2006;18:703-10.